20th May 2013
Global technology company 3M announced today its Tegaderm CHG (chlorhexidine gluconate) I.V. securement dressing is the first transparent antimicrobial dressing to be clinically proven and indicated to reduce catheter-related bloodstream infections (CRBSIs).
Its performance has been validated following an extensive randomised controlled trial1 led by renowned clinician Professor Jean-François Timsit, President of L'association OutcomeRéa*. Study data was reviewed by the UK Medicines and Healthcare products Regulatory Agency and CE mark certification awarded by the British Standards Institution.
Tegaderm CHG dressing combines the antimicrobial power of clorhexidine gluconate with the transparency, reliability and simplicity of 3M’s Tegaderm film. Designed for central venous, arterial and other intravascular catheters, it is intended to reduce skin colonisation and catheter colonisation and to suppress regrowth of microorganisms commonly related to blood stream infections. The study by Timsit et al., based on 34,339 catheter days, compared three types of I.V. dressing and showed that the chlorhexidine dressing had a 67% lower major catheter-related infection rate than the non-chlorhexidine dressings1. A health-economic assessment by Maunoury et al.,2 based on the Timsit study data, showed that using Tegaderm CHG dressings avoided, on average, 12 infections per 1,000 patients when compared to using non-chlorhexidine dressings. Tegaderm CHG dressing was also shown to be more cost-effective than the comparator.
“The implications of this study are significant for healthcare providers across Europe,” said Gary Stapleton, Director, 3M Health Care Business Group Western Europe. “Whilst intravascular catheters are indispensable components of hospital care, we know that catheter-related infections can prolong hospital stays by up to 20 days with attributable costs of up to €42,000.3 By choosing Tegaderm CHG I.V. dressing, healthcare providers can have confidence in a product backed by robust clinical data that can help to reduce the cost, morbidity and associated patient anxiety of catheter-related bloodstream infections,” he added.
Because bloodstream infections can have devastating medical consequences for patients, they are a major public health concern. In a recent point prevalence survey of healthcare- associated infections (HAI) in European acute care hospitals, 1.6% of 13,829 recorded incidences of HAIs were catheter-related.4 In a review of data from four major European countries, it was estimated that between 1,000 and 1,584 deaths per year in intensive care units were due to CRBSI.5
Tegaderm CHG dressing forms part of a trusted line of 3M Vascular Access Solutions. The dressing provides continuous antimicrobial activity for up to 7 days6 whilst maintaining complete site visibility. Its intuitive design and one-step application help support compliance with facility protocols. In vitro testing7 has shown that chlorhexidine gluconate has broad spectrum activity against, and is a barrier to, a wide variety of gram-positive and gram-negative bacteria and yeast. These include the majority of pathogens of most concern to epidemiologists and infection control practitioners.
As Tegaderm CHG dressing is now clinically proven to reduce catheter-related bloodstream infections, it becomes a highly valued addition to a multi-faceted approach to patient safety in hospitals.
Notes to Editors
1. Media contact: Rosalind Smith, 3M, Tel: 01509 613009 email: email@example.com
2. About 3M
3M is the innovation company that never stops inventing. Our Health Care business, one of five major business groups, is dedicated to improving the practice, delivery and outcome of patient care and is a leading provider of solutions for medical, oral care, drug delivery and health information markets. For further information visit www.3M.co.uk/healthcare
3. 3M and Tegaderm are trademarks of the 3M Company.
4. *www.outcomerea.org References:
1. Timsit JF, et al. Randomized Controlled Trial of Chlorhexidine Dressing and Highly Adhesive Dressing for Preventing Catheter-Related Infections in Critically Ill Adults. American Journal of Respiratory and Critical Care Medicine 2012; 186 (12):1272-1278.
2. Maunoury F, Motrunich A, Ruckly S, Timsit JF. Non-homogeneous cost-effectiveness modelling of a new CHG-Dressing for preventing catheter-related bloodstream infections for patients in intensive care units. Poster session, presented at 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research; 2013 November 2-6; Dublin, Ireland.
3. Dr. Philippe Eggimann, head of the Intensive Care Unit of the University Hospital of Lausanne, Switzerland. Presentation at the 10th European Infection Prevention Expert Conference in October 2013.
4. ECDC SURVEILLANCE REPORT. Point prevalence survey of healthcare associated infections and antimicrobial use in European acute care hospitals 2011–2012, www.ecdc.europa.eu
5. Tacconelli E, Smith G, Hieke K, Lafuma A, Bastide P. Epidemiology, medical outcomes and costs of catheter-related bloodstream infections in intensive care units of four European countries: literature- and registry-based estimates. J Hosp Infect. 2009 Jun; 72(2):97-103.
6. Karpanen TJ, et al. Antimicrobial activity of a Chlorhexidine intravascular catheter site gel dressing, Journal of Antimicrobial Chemotherapy, 2011. 66: 1777-1784.
7. Hensler J. et al. Growth inhibition of microorganisms involved in catheter-related infections by an antimicrobial transparent IV dressing containing chlorhexidine gluconate (CHG). ECCMID, Helsinki, May 2009.